Rational design of HIV vaccines and microbicides: report of the EUROPRISE network annual conference 2010

Brinckmann, Sarah; da Costa, Kelly; van Gils, Marit J.; Hallengärd, David; Klein, Katja; Madeira, Luisa; Mainetti, Lara; Palma, Paolo; Raue, Katharina; Reinhart, David; Reudelsterz, Marc; Ruffin, Nicolas; Seifried, Janna; Schäfer, Katrein; Sheik-Khalil, Enas; Sköld, Annette; Uchtenhagen, Hannes; Vabret, Nicolas; Ziglio, Serena; Scarlatti, Gabriella
January 2011
Journal of Translational Medicine;2011, Vol. 9 Issue 1, p40
Academic Journal
Novel, exciting intervention strategies to prevent infection with HIV have been tested in the past year, and the field is rapidly evolving. EUROPRISE is a network of excellence sponsored by the European Commission and concerned with a wide range of activities including integrated developmental research on HIV vaccines and microbicides from discovery to early clinical trials. A central and timely theme of the network is the development of the unique concept of co-usage of vaccines and microbicides. This review, prepared by the PhD students of the network captures much of the research ongoing between the partners. The network is in its 5th year and involves over 50 institutions from 13 European countries together with 3 industrial partners; GSK, Novartis and Sanofi-Pasteur. EUROPRISE is involved in 31 separate world-wide trials of Vaccines and Microbicides including 6 in African countries (Tanzania, Mozambique, South Africa, Kenya, Malawi, Rwanda), and is directly supporting clinical trials including MABGEL, a gp140-hsp70 conjugate trial and HIVIS, vaccine trials in Europe and Africa.


Related Articles

  • HIV vaccine failure prompts Merck to halt trial.  // Nature;9/27/2007, Vol. 449 Issue 7161, p390 

    The article reports on the failure of the human immunodeficiency virus (HIV) vaccine developed by Merck in the U.S. It is stated that the failure has caused Merck to halt its clinical trials. It reveals that the latest trial had begun in 2004 which enrolled 3,000 people considered to be at high...

  • Why We Don't Have An HIV Vaccine, And How We Can Develop One. Harris, Jeffrey E. // Health Affairs;Nov/Dec2009, Vol. 28 Issue 6, p1642 

    Confronted with the recent high-profile failures of several clinical trials of promising candidate vaccines against HIV, many scientists have all but given up hope of producing a human-ready vaccine within the next decade. In this review I contend that although the scientific obstacles remain...

  • A qualitative evaluation of volunteers' experiences in a phase I/II HIV vaccine trial in Tanzania.  // BMC Infectious Diseases;2011, Vol. 11 Issue 1, p283 

    The article discusses a study which evaluated the experiences of volunteers in an HIV vaccine trial in Dar es Salaam, Tanzania. The study found that during the phase I/II HIV vaccine trial, participants had the opportunities and the ability to cope with the doubts from the surrounding community....

  • New HIV/AIDS vaccine shows promise. Townes, Glenn // New York Amsterdam News;10/1/2009, Vol. 100 Issue 40, p31 

    The article discusses the result of the study conducted by the U.S. Military HIV Research Program in Rockville, Maryland, which states that a new drug regimen designed to prevent HIV infection has shown critical success in fighting the illness. It mentions that the drug regimen involves a...

  • Safety of Newer Parenteral Antibiotics. Stein, Gary E. // Clinical Infectious Diseases;9/1/2005 Supplement, Vol. 41, pS293 

    Several parenteral antimicrobials have been introduced into clinical practice over the course of the last decade. Some of these agents (e.g., linezolid, daptomycin, and tigecycline) are prototypes of new classes of compounds. In comparative clinical trials, these newer anti-infectives have been...

  • Innovotech receives green light for sale of bioFILM PA test.  // Edmontonians;Sep2009, Vol. 20 Issue 9, p20 

    The article focuses on the significance of the bioFILM PA test development to medical community in Edmonton, Alberta. It notes that the biofilm shows very positive results in choosing the appropriate antibiotic treatment for serious lung infections. Its clinical research reveals the test's...

  • Anidulafungin: A Viewpoint by José A. Vazquez. Vazquez, José A // Drugs;2004, Vol. 64 Issue 19, p2259 

    Presents the viewpoint of José A. Vazquez regarding the drug, anidulafungin. Description of the drug; Advantages of the drug over other antifungal medications; Benefits offered by the drug; Effectiveness of the drug in treating azole-refractory mucosal fungal infections in HIV-positive patients.

  • Antiviral Briefs.  // AIDS Patient Care & STDs;Aug2007, Vol. 21 Issue 8, p602 

    The article offers news briefs on antiviral agents. Boehringer Ingelheim has started enrollment of its POTENT study. Gilead Sciences released their 144-week data from an ongoing clinical trial, Study 934, and comparing a once-daily regimen of Truvada. Abbott has received approval from 19 African...

  • Impact of pre-term antibiotics.  // Primary Health Care;Nov2008, Vol. 18 Issue 9, p6 

    The article presents a clinical trial on the impact of pre-term antibiotics among women with preterm rupture of membranes (PROM) in Great Britain. Experiment shows that co-amoxiclav was associated with longer pregnancy and neonatal necrotising enterocolitis. It was found out that there were no...

  • Early use of imipenem/cilastatin and vancomycin followed by de-escalation versus conventional antimicrobials without de-escalation for patients with hospital-acquired pneumonia in a medical ICU: a randomized clinical trial.  // Critical Care;2012, Vol. 16 Issue 1, pR28 

    The article presents a study that investigated the effects of early use of broad-spectrum antimicrobials in critically ill patients with hospital-acquired pneumonia (HAP). In the study, between November 2004 and October 2006, 109 MICU patients with HAP were enrolled. Initial antimicrobial...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics